Personalized Therapy in Renal Cell Carcinoma: Are the Different Tyrosine Kinase Inhibitors the Same for Any Patient?

Expert Review of Precision Medicine and Drug Development- United Kingdom

doi 10.1080/23808993.2017.1289066

Full Text

Abstract

Available in

Date

Authors

Publisher

Informa UK Limited

Related search

Personalized Therapy of Tyrosine Kinase Inhibitors

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
2013English

Brain Metastases From Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors

Clinical Genitourinary Cancer
OncologyUrology
2013English

Concomitant Oral Tyrosine Kinase Inhibitors and Bisphosphonates in Advanced Renal Cell Carcinoma With Bone Metastases

British Journal of Cancer
Cancer ResearchOncology
2012English

Do Tyrosine Kinase Inhibitors Lose Favor in Treatment of First-Line Metastatic Renal Cell Carcinoma?

Future Oncology
MedicineCancer ResearchOncology
2019English

Patient-Specific Molecular Alterations Are Associated With Metastatic Clear Cell Renal Cell Cancer Progressing Under Tyrosine Kinase Inhibitor Therapy

Oncotarget
Oncology
2017English

The Expression and Role of Tyrosine Kinase ETK/BMX in Renal Cell Carcinoma

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2014English

Future Perspectives for Personalized Immunotherapy in Renal Cell Carcinoma

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2017English

Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population

Clinical Genitourinary Cancer
OncologyUrology
2014English

Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy